1. Home
  2. News
  3. Clarity Pharmaceuticals Ltd.
  4. Phase II SABRE prostate cancer trial reaches 50% recruitment
More Clarity Pharmaceuticals Ltd. news
Clarity Pharmaceuticals Ltd.ASX: CU6

Phase II SABRE prostate cancer trial reaches 50% recruitment

Jul 23, 2023 at 10:46 PM EDT · Issued by Clarity Pharmaceuticals Ltd.

Filed with ASX · Jul 23, 2023 at 10:46 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/phase-ii-sabre-prostate-cancer-trial-reaches-50percent-recruitment

Clarity Pharmaceuticals Ltd. on 6ix

Earlier from Clarity Pharmaceuticals

  • Positive Guidance from FDA on Phase 3 Prostate Cancer TrialJul 3, 2023
  • Clarity Establishes US Center of Excellence for ResearchJun 27, 2023
  • Northstar Achieves Key Production MilestonesJun 26, 2023
  • COMBAT theranostic prostate cancer trial commences in the USJun 19, 2023
  • Clarity expands supply of Cu-64 for Phase III trialsJun 13, 2023

Later from Clarity Pharmaceuticals

  • Final Cohort opens for CL04 Paediatric Neuroblastoma trialJul 25, 2023
  • Clarity Bolsters Antibody Pre-Targeting with IP from MSKAug 6, 2023
  • Theranostic prostate cancer trial advances to cohort 3Aug 9, 2023
  • First PC participant treated at the highest dose levelAug 24, 2023
  • First neuroblastoma participant treated in highest cohortAug 25, 2023
All Clarity Pharmaceuticals news releases↗

Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.

Follow Clarity Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer